[1] [3] Key risk factors for developing hypotension on GLP-1 therapy include: Concurrent use of antihypertensive medications, especially diuretics, ACE inhibitors, or ARBs Concomitant use of SGLT2 inhibitors, which can cause osmotic diuresis and volume depletion Baseline blood pressure in the low-normal range (systolic 90-110 mmHg) Advanced age (65 years and older) Autonomic dysfunction or diabetic neuropathy Rapid or substantial weight loss Inadequate fluid intake or gastrointestinal side effects causing dehydration Concomitant use of other medications that lower blood pressure Patients with type 1 diabetes using off-label GLP-1 therapy or those with longstanding type 2 diabetes and cardiovascular autonomic neuropathy may be at higher risk for orthostatic hypotension
Advertisement Article continues below this ad Food and Drug Administration investigators found serious deficiencies in (Empower's) practices for producing drug products intended or expected to be sterile, which put patients at risk, according to a letter sent to the company in April, referring to drugs that are supposed to meet strict quality standards
Patt, Leonard M., and A
Produzida naturalmente a partir dos aminocidos lisina e metionina, sua funo principal transportar cidos graxos para a mitocndria, promovendo a queima de gordura como fonte de energia
Another population-based cohort study of patients with T2DM with a concomitant cancer showed that no increased risk of metastasis was associated with DPP-4 inhibitor therapy (Noh et al., 2019)
